Company logo

LXRX - Lexicon Pharmaceuticals, Inc.

NASDAQ -> Healthcare -> Biotechnology
The Woodlands, United States
Type: Equity

LXRX price evolution
LXRX
(in millions $) 31 Mar 2023 31 Jan 2023 30 Sep 2022 30 Jun 2022
Current assets
Cash $26 $46.34 $18.83 $21.45
Short term investments $79.94 $92.01 $117.37 $40.52
Net receivables $0.26 $0.03 $0.04 $0.03
Inventory
Total current assets $109.55 $140.87 $139.06 $64.9
Long term investments
Property, plant & equipment $8.63 $4.37 $0.93 $1.03
Goodwill & intangible assets $44.54 $44.54 $44.54 $44.54
Total noncurrent assets $53.17 $53.43 $52.62 $47.43
Total investments $79.94 $92.01 $117.37 $40.52
Total assets $162.72 $194.3 $191.69 $112.33
Current liabilities
Accounts payable $10.31 $10.39 $9.43 $7.35
Deferred revenue
Short long term debt
Total current liabilities $20.37 $23.17 $18.45 $16.86
Long term debt $54.3 $48.58 $23.78 $23.63
Total noncurrent liabilities $54.3 $54 $29.22 $24.63
Total debt $54.3 $54 $23.78 $23.63
Total liabilities $74.67 $77.17 $47.67 $41.49
Shareholders' equity
Retained earnings -$1621.65 -$1589.72 -$1559.23 -$1535.84
Other shareholder equity -$0.16 -$0.43 -$0.49 -$0.15
Total shareholder equity $88.05 $117.12 $144.02 $70.83
(in millions $) 31 Jan 2023 31 Dec 2021 31 Dec 2020 31 Dec 2019
Current assets
Cash $46.34 $64.06 $126.26 $36.11
Short term investments $92.01 $22.68 $26.01 $235.55
Net receivables $0.03 $0.01 $0.4 $56.53
Inventory $4.24
Total current assets $140.87 $88.92 $157.72 $337.75
Long term investments
Property, plant & equipment $4.37 $1.18 $0.29 $14.05
Goodwill & intangible assets $44.54 $44.54 $44.54 $64.26
Total noncurrent assets $53.43 $47.99 $46.07 $79.96
Total investments $92.01 $22.68 $26.01 $235.55
Total assets $194.3 $136.91 $203.79 $417.71
Current liabilities
Accounts payable $10.39 $9.15 $5.47 $12.18
Deferred revenue
Short long term debt $11.65 $11.01
Total current liabilities $23.17 $22.12 $46.81 $65.34
Long term debt $48.58 $234.17
Total noncurrent liabilities $54 $1.19 $0.61 $235.27
Total debt $54 $11.65 $245.18
Total liabilities $77.17 $23.31 $47.42 $300.61
Shareholders' equity
Retained earnings -$1589.72 -$1487.78 -$1400.02 -$1341.44
Other shareholder equity -$0.43 -$0.01 -$0.01 $0.08
Total shareholder equity $117.12 $113.59 $156.37 $117.1
(in millions $) 31 Mar 2023 31 Dec 2022 30 Sep 2022 30 Jun 2022
Revenue
Total revenue $0.02 $0.03 $0.04 $0.04
Cost of revenue
Gross Profit $0.02 $0.03 $0.04 $0.04
Operating activities
Research & development $12.03 $13.98 $10.56 $13.36
Selling, general & administrative $19.14 $16.33 $12.58 $10.69
Total operating expenses $31.17 $30.31 $23.13 $24.04
Operating income -$31.14 -$30.28 -$23.09 -$24.01
Income from continuing operations
EBIT -$30.11 -$29.39 -$22.52 -$23.88
Income tax expense
Interest expense $1.82 $1.1 $0.86 $0.7
Net income
Net income -$31.93 -$30.49 -$23.39 -$24.59
Income (for common shares) -$31.93 -$30.49 -$23.39 -$24.59
(in millions $) 31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Revenue
Total revenue $0.14 $0.3 $24 $322.07
Cost of revenue $1.93 $3.23
Gross Profit $0.14 $0.3 $22.07 $318.84
Operating activities
Research & development $52.82 $55.05 $153.62 $91.92
Selling, general & administrative $48.08 $32.34 $47.23 $56.84
Total operating expenses $100.9 $87.39 $69.87 $177.4
Operating income -$100.76 -$87.09 -$47.8 $141.44
Income from continuing operations
EBIT -$99.16 -$86.96 -$44.03 $144.79
Income tax expense -$6.01
Interest expense $2.78 $0.8 $14.54 $20.68
Net income
Net income -$101.94 -$87.76 -$58.57 $130.13
Income (for common shares) -$101.94 -$87.76 -$58.57 $130.13
(in millions $) 31 Mar 2023 31 Dec 2022 30 Sep 2022 30 Jun 2022
Net income -$31.93 -$30.49 -$23.39 -$24.59
Operating activities
Depreciation $0.11 $0.1 $0.11 $0.11
Business acquisitions & disposals
Stock-based compensation $3.42 $3.27 $2.65 $2.83
Total cash flows from operations -$31.61 -$21.57 -$19.44 -$24.42
Investing activities
Capital expenditures -$0.25 -$1.25 -$0
Investments $12.34 $25.42 -$77.19 -$13.65
Total cash flows from investing $12.09 $24.17 -$77.2 -$13.65
Financing activities
Dividends paid
Sale and purchase of stock -$0.82 -$0.06 $94.27
Net borrowings $24.97 -$0.25
Total cash flows from financing -$0.82 $24.91 $94.02
Effect of exchange rate
Change in cash and equivalents -$20.34 $27.51 -$2.62 -$38.07
(in millions $) 31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Net income -$101.94 -$87.76 -$58.57 $130.13
Operating activities
Depreciation $0.43 $0.29 $2.93 $3.65
Business acquisitions & disposals $160.38
Stock-based compensation $11.52 $10.58 $13.27 $14.22
Total cash flows from operations -$88.85 -$87.02 -$142.97 $113.81
Investing activities
Capital expenditures -$1.33 -$1.22 $10.93 -$0.07
Investments -$69.75 $3.33 $209.44 -$155.78
Total cash flows from investing -$71.08 $2.11 $380.76 -$155.85
Financing activities
Dividends paid
Sale and purchase of stock $93.34 $34.41 $68.94 -$0.94
Net borrowings $48.87 -$11.7 -$216.58 -$1.28
Total cash flows from financing $142.21 $22.71 -$147.64 -$2.23
Effect of exchange rate
Change in cash and equivalents -$17.72 -$62.2 $90.15 -$44.27
Fundamentals
Market cap $521.30M
Enterprise value $549.59M
Shares outstanding 189.56M
Revenue $126.00K
EBITDA -$105.48M
EBIT -$105.91M
Net Income -$110.40M
Revenue Q/Q -35.14%
Revenue Y/Y -59.09%
P/E ratio -4.72
EV/Sales 4.36K
EV/EBITDA -5.21
EV/EBIT -5.19
P/S ratio 4.14K
P/B ratio 5.91
Book/Share 0.47
Cash/Share 0.14
EPS -$0.58
ROA -66.81%
ROE -105.14%
Debt/Equity 0.66
Net debt/EBITDA -0.46
Current ratio 5.38
Quick ratio 5.38